Vertex Pharmaceuticals (VRTX) Change in Receivables (2009 - 2026)

Vertex Pharmaceuticals' Change in Receivables history runs 18 years deep, the most recent figure standing at -$39.8 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 123.47% year-over-year to -$39.8 million in Q1 2026; TTM through Mar 2026 was $137.9 million, a 697.11% increase from a year earlier, with the FY2025 full-year figure at $347.3 million, up 249.75% from the prior year.
• Change in Receivables retreated to -$39.8 million in Q1 2026 per VRTX's latest filing, from $99.4 million in the prior quarter.
• Across five years, Change in Receivables topped out at $251.6 million in Q1 2024 and bottomed at -$135.1 million in Q2 2024.
• The 5-year median for Change in Receivables is $51.8 million (2024), against an average of $50.0 million.
• Biggest YoY gain for Change in Receivables was 749.18% in 2024; the steepest drop was 4758.62% in 2024.
• Year by year, Change in Receivables stood at -$10.2 million in 2022, then plunged by 50.98% to -$15.4 million in 2023, then plunged by 348.05% to -$69.0 million in 2024, then soared by 244.06% to $99.4 million in 2025, then slumped by 140.04% to -$39.8 million in 2026.
• Per Business Quant, the three latest VRTX Change in Receivables figures stand at -$39.8 million (Q1 2026), $99.4 million (Q4 2025), and $59.9 million (Q3 2025).